Journal of Shandong University (Health Sciences) ›› 2026, Vol. 64 ›› Issue (3): 17-23.doi: 10.6040/j.issn.1671-7554.0.2025.0415

• “Psychological Health in Children and Adolescents” Key Topics • Previous Articles    

Research progress of Shugan Jieyu Capsule in the treatment of depressive disorder in adolescents

FAN Chengmin1, SONG Jingyu2, YU Shuyan3, MAO Xueqin1   

  1. 1. Department of Psychology, Qilu Hospital of Shandong University, Jinan 250012, Shandong, China;
    2. Mental Health Development Center, Hunan Automotive Engineering Vocational University, Zhuzhou 412003, Hunan, China;
    3. Department of Physiology, School of Basic Medical Sciences, Cheeloo College of Medicine, Shandong University, Jinan 250012, Shandong, China
  • Published:2026-03-19

PDF (PC)

0

Abstract: As first-line clinical drugs, selective serotonin reuptake inhibitors(SSRIs)have significant limitations due to their high rate of adverse reactions and limited evidence-based medical data for the adolescent population. Shugan Jieyu Capsules, as a multi-target traditional Chinese medicine compound formulation, have shown good efficacy and safety in the treatment of adult depression. However, systematic reviews of their use in adolescent patients are lacking. This article discusses three dimensions: the pathophysiological mechanisms and current treatment status of adolescent depression, the antidepressant pharmacological mechanisms of Shugan Jieyu Capsules, and their efficacy and safety in the treatment of adolescent depression, and focuses on elaborating the core mechanisms through which Shugan Jieyu Capsules exert antidepressant effects by regulating neurotransmitter homeostasis, inhibiting neuroinflammation, and improving gut microbiota. Based on randomized controlled trial data, it compares the differences in efficacy and safety between Shugan Jieyu Capsules and SSRI drugs(such as sertraline), aiming to provide evidence-based references for individualized treatment of adolescent depression and promote the application and development of traditional Chinese medicine compounds in adolescent mental health.

Key words: Shugan Jieyu Capsules, Adolescent depressive disorder, Sertraline, Drug therapy

CLC Number: 

  • R749.94
[1] 吴婷, 张文武, 杜亚松. 青少年抑郁障碍的研究与诊疗现状[J]. 现代实用医学, 2022, 34(4): 421-424. WU Ting, ZHANG Wenwu, DU Yasong. Research, diagnosis and treatment of adolescent depression[J]. Modern Practical Medicine, 2022, 34(4): 421-424.
[2] Song XX, Li YY, Wang XY, et al. Evolution of core symptoms of depression disorders among Chinese adolescents across different grades[J]. Depress Anxiety, 2025, 2025(1): 2309327. doi: 10.1155/da/2309327
[3] 郭菲,王薪舒,陈祉妍. 2022年中国青少年心理健康状况调查报告[R]. 北京: 社会科学文献出版社, 2023: 30-69.
[4] 中华人民共和国教育部. 教育部等十七部门关于印发《全面加强和改进新时代学生心理健康工作专项行动计划(2023—2025年)》的通知 [EB/OL].(2023-04-20)[2025-03-04]. https://www.gov.cn/zhengce/zhengceku/202305/content_6857361.htm
[5] Garland EJ, Kutcher S, Virani A, et al. Update on the use of SSRIs and SNRIs with children and adolescents in clinical practice[J]. J Can Acad Child Adolesc Psychiatry, 2016, 25(1): 4-10.
[6] Amitai M, Chen A, Weizman A, et al. SSRI-induced activation syndrome in children and adolescents: what is next?[J]. Curr Treat Options Psychiatry, 2015, 2(1): 28-37.
[7] Yin CY, Xu MT, Zong ZY. Advances in the prevalence and treatment of depression for adolescents: a review[J]. Front Pharmacol, 2025, 16: 1574574. doi: 10.3389/fphar.2025.1574574
[8] Feng DD, Tang T, Lin XP, et al. Nine traditional Chinese herbal formulas for the treatment of depression: an ethnopharmacology, phytochemistry, and pharmacology review[J]. Neuropsychiatr Dis Treat, 2016, 12: 2387-2402. doi: 10.2147/NDT.S114560
[9] 中华中医药学会心身医学分会专家组. 舒肝解郁胶囊治疗轻中度抑郁障碍临床应用专家共识[J]. 北京中医药大学学报, 2021, 44(11): 969-977. Expert Group of Psychosomatic Medicine Branch of China Association of Chinese Medicine. Expert consensus on clinical application of Shugan Jieyu Capsule in treatment of mild to moderate depressive disorders[J]. Journal of Beijing University of Traditional Chinese Medicine, 2021, 44(11): 969-977.
[10] Wu D, Chen QH, Yu ZY, et al. Transport and inhibition mechanisms of human VMAT2[J]. Nature, 2023, 626(7998): 427-434.
[11] Li Y, Wang XP, Meng YF, et al. Dopamine reuptake and inhibitory mechanisms in human dopamine transporter[J]. Nature, 2024, 632(8025): 686-694.
[12] Rizzo A, Garçon-Poca MZ, Essmann A, et al. The dopaminergic effects of esketamine are mediated by a dual mechanism involving glutamate and opioid receptors[J]. Mol Psychiatry, 2025, 30(8): 3443-3454.
[13] Qiu Y, Zhu L, Cai W, et al. Research progress on BDNF and depression[J]. ACS Chem Neurosci, 2025, 16(11): 2013-2023.
[14] 黄磊, 郑春美, 庞卢伟, 等. 青少年抑郁障碍患者血清FGF2和BDNF表达与病情程度及CI的关系[J]. 浙江临床医学, 2024(2): 221-223. HUANG Lei, ZHENG Chunmei, PANG Luwei, et al. Relationship between serum FGF2 and BDNF expression and severity of illness and CI in adolescent patients with depressive disorder[J]. Zhejiang Clinical Medical Journal, 2024(2): 221-223.
[15] Cao P, Chen CM, Liu A, et al. Early-life inflammation promotes depressive symptoms in adolescence via microglial engulfment of dendritic spines[J]. Neuron, 2021, 109(16): 2573-2589.
[16] 刘梦琪, 何凡, 田兰君, 等. 炎症因子在青少年抑郁障碍发病中的作用[J]. 中国心理卫生杂志, 2024, 38(4): 350-356. LIU Mengqi, HE Fan, TIAN Lanjun, et al. A review of inflammatory factors in onset of depressive disorder in adolescents[J]. Chinese Mental Health Journal, 2024, 38(4): 350-356.
[17] 赖韵如, 程译文, 朱张骋, 等. 儿童重度抑郁症患者肠道菌群及其系统性免疫应答研究[J]. 中国微生态学杂志, 2025, 37(2): 215-221. LAI Yunru, CHENG Yiwen, ZHU Zhangcheng, et al. Gut dysbiosis and systemic inflammation among children with major depressive disorder[J]. Chinese Journal of Microecology, 2025, 37(2): 215-221.
[18] Wang L, Zhou LP, Zhu Y, et al. Trends in prescription therapy for adolescents with depression in nine major areas of China during 2017-2021[J]. Front Psychiatry, 2023, 14: 1175002. doi: 10.3389/fpsyt.2023.1175002
[19] Strawn JR, Mills JA, Poweleit EA, et al. Adverse effects of antidepressant medications and their management in children and adolescents[J]. Pharmacotherapy, 2023, 43(7): 675-690.
[20] Iñiguez SD, Warren BL, Bolaños-Guzmán CA. Short- and long-term functional consequences of fluoxetine exposure during adolescence in male rats[J]. Biol Psychiatry, 2010, 67(11): 1057-1066.
[21] Carreno FR, Frazer A. Vagal nerve stimulation for treatment-resistant depression[J]. Neurotherapeutics, 2017, 14(3): 716-727.
[22] 王元翀, 邱喜龙, 王博瑶. 中药调控单胺类神经递质治疗抑郁症的研究进展[J]. 药物评价研究, 2024, 47(9): 2182-2196. WANG Yuanchong, QIU Xilong, WANG Boyao. Research progress in treatment of depression with traditional Chinese medicine by regulating monoamine neurotransmitters[J]. Drug Evaluation Research, 2024, 47(9): 2182-2196.
[23] Zhou SY, Zhu YB, Du AN, et al. A midbrain circuit mechanism for noise-induced negative valence coding[J]. Nat Commun, 2025, 16(1): 4610. doi: 10.1038/s41467-025-59956-z
[24] 傅锦华. 新型抗抑郁中药舒肝解郁胶囊对抑郁模型大鼠的作用机制研究[D]. 长沙: 中南大学, 2014.
[25] 鄢玲, 李伟. 舒肝解郁胶囊治疗阿尔茨海默病伴抑郁患者的临床疗效及对其氧化应激的影响[J]. 世界中西医结合杂志, 2020, 15(12): 2261-2264. YAN Ling, LI Wei. Effect of Shugan Jieyu Capsules on improving the cognition and emotion of Alzheimers Disease patients with depression and its effect on oxidative stress[J]. World Journal of Integrated Traditional and Western Medicine, 2020, 15(12): 2261-2264.
[26] 傅锦华, 刘勇. 舒肝解郁胶囊对抑郁模型大鼠脑内5-HT、DA及其代谢产物水平的影响[J]. 湖南中医药大学学报, 2016, 36(6): 47-51. FU Jinhua, LIU Yong. Effect of Shugan Jieyu capsules on 5-HT, DA and their metabolites in the brain of depression model rats[J]. Journal of Hunan University of Chinese Medicine, 2016, 36(6): 47-51.
[27] 王含彦, 郭冬梅, 唐珍. 舒肝解郁胶囊对抑郁模型大鼠脑内脑源性神经营养因子的影响[J]. 中国医药导报, 2019, 16(20): 21-24. WANG Hanyan, GUO Dongmei, TANG Zhen. Effect of Shugan Jieyu Capsules on brain-derived neurotrophic factor in model rats with depression[J]. China Medical Herald, 2019, 16(20): 21-24.
[28] Fu JH, Zhang YJ, Wu RR, et al. Shuganjieyu capsule increases neurotrophic factor expression in a rat model of depression[J]. Neural Regen Res, 2014, 9(5): 489-497. doi: 10.4103/1673-5374.130067
[29] 白天山, 李志榕, 黄平, 等. 舒肝解郁胶囊通过激活JAK1/STAT3信号通路改善大鼠抑郁症及修复海马神经元细胞[J]. 西北药学杂志, 2022, 37(4): 58-63. BAI Tianshan, LI Zhirong, HUANG Ping, et al. Shugan Jieyu Capsules improves depression and repairs hippo-campal neurons in rats by activating JAK1/STAT3 signaling pathway[J]. Northwest Pharmaceutical Journal, 2022, 37(4): 58-63.
[30] 陈艳, 戴数. 舒肝解郁胶囊联合文拉法辛治疗抑郁症临床研究[J]. 新中医, 2021, 53(18): 59-62. CHEN Yan, DAI Shu. Clinical study on Shugan Jieyu capsules combined with venlafaxine for depression[J]. Journal of New Chinese Medicine, 2021, 53(18): 59-62.
[31] 杨家豪, 刘磊. 舒肝解郁胶囊辅助治疗对老年抑郁症心理健康和预后的影响观察[J]. 临床研究, 2020, 28(3): 114-116. YANG Jiahao, LIU Lei. Effect of Shugan Jieyu capsule adjuvant therapy on mental health and prognosis of elderly depression[J]. Clinical Research, 2020, 28(3): 114-116.
[32] Tan JX, Li XX, Zhu Y, et al. Antidepressant Shugan Jieyu capsule alters gut microbiota and intestinal micro-biome function in rats with chronic unpredictable mild stress-induced depression[J]. Front Pharmacol, 2022, 13: 828595. doi: 10.3389/fphar.2022.828595
[33] 王含彦, 郭冬梅, 唐珍, 等. 舒肝解郁胶囊的抗抑郁作用及其机制[J]. 中成药, 2018, 40(1): 187-190. WANG Hanyan, GUO Dongmei, TANG Zhen, et al. Antidepressant effect of Shugan Jieyu capsule and its mechanism[J]. Chinese Traditional Patent Medicine, 2018, 40(1): 187-190.
[34] 吴汉彪. 基于整合数据探讨疏肝理气型中成药辅助治疗抑郁症的作用机制[D]. 广州: 广东药科大学. 2023.
[35] 瞿波. 舒肝解郁胶囊和盐酸舍曲林治疗青少年抑郁症的对照研究[J]. 内蒙古中医药, 2011, 30(19): 67-68. QU Bo. The comparative study on Shuganjieyu Jiaonang capsules and Sertraline Hydrochloride tablets in treating juvenile s depression[J]. Nei Mongol Journal of Traditional Chinese Medicine, 2011, 30(19): 67-68.
[36] 陶百平, 耿松, 王轶虎. 舒肝解郁胶囊治疗青少年抑郁疗效观察[J]. 浙江中西医结合杂志, 2015, 25(5): 464-465. TAO Baiping, GENG Song, WANG Yihu. Observation on therapeutic effect of Shugan Jieyu capsule on adolescent depression[J]. Zhejiang Journal of Integrated Traditional Chinese and Western Medicine, 2015, 25(5): 464-465.
[37] 周进波,卢燕. 舒肝解郁胶囊联合盐酸舍曲林治疗青少年首发抑郁症的效果观察[J/OL]. 中文科技期刊数据库(引文版)医药卫生, 2023, 2023(4): 100-102[2023-04-01]. https://www.cqvip.com/doc/journal/2010228827601830400
[38] 史盼, 刘晓鹏, 宋丁. 舒肝解郁胶囊联合盐酸舍曲林治疗青少年首发抑郁症临床观察[J]. 实用中医药杂志, 2020, 36(6): 765-766. SHI Pan, LIU Xiaopeng, SONG Ding. Clinical observation on Shugan Jieyu capsule combined with sertraline hydrochloride in the treatment of adolescent first-episode depression[J]. Journal of Practical Traditional Chinese Medicine, 2020, 36(6): 765-766.
[39] 胡希燊, 李媛, 刘佳丽. 盐酸舍曲林片联合舒肝解郁胶囊治疗青少年抑郁发作的疗效评价[J]. 心理月刊, 2024, 19(4): 148-150.
[40] 周炼. 盐酸舍曲林片联合舒肝解郁胶囊治疗青少年抑郁发作的临床疗效[J]. 黑龙江医药, 2022, 35(3): 625-628. ZHOU Lian. Clinical efficacy of sertraline hydrochloride tablets combined with Shugan Jieyu capsule in the treatment of adolescent depression[J]. Heilongjiang Medicine Journal, 2022, 35(3): 625-628.
[41] 胡文芳. 重复经颅磁刺激联合舒肝解郁胶囊治疗青少年网络成瘾的临床观察[J]. 现代诊断与治疗, 2022, 33(17): 2578-2580. HU Wenfang. Clinical observation of repetitive transcranial magnetic stimulation combined with Shugan Jieyu capsule in the treatment of adolescent Internet addiction[J]. Modern Diagnosis and Treatment, 2022, 33(17): 2578-2580.
[42] 王超, 余葱葱, 柯潇, 等. 基于“脏虚为本,气郁为标” 理论抗抑郁中药舒肝解郁胶囊临床应用及作用机理研究进展[J]. 中药药理与临床, 2023, 39(4): 120-124. WANG Chao, YU Congcong, KE Xiao, et al. Clinical application and mechanism of Shuganjieyu capsules in the treatment of depression from the theory of zangxu as the root cause and qiyu as the symptom: a review[J]. Pharmacology and Clinics of Chinese Materia Medica, 2023, 39(4): 120-124.
[43] 张龙瑛, 楼莉峰, 游倩, 等. 儿童和青少年抑郁障碍用药处方趋势及不良反应分析[J]. 中国药物警戒, 2024, 21(12): 1419-1424. ZHANG Longying, LOU Lifeng, YOU Qian, et al. Medications and adverse reaction in children and adolescents with depressive disorders[J]. Chinese Journal of Pharmacovigilance, 2024, 21(12): 1419-1424.
[44] 《青少年抑郁障碍中西医结合防治指南》编写组, 中华中医药学会心身医学分会, 中华医学会心身医学分会. 青少年抑郁障碍中西医结合防治指南[J]. 北京中医药大学学报, 2024, 47(6): 874-888.
[45] 朱海斌, 于佳竹. 舒肝解郁胶囊在某院门/急诊使用情况分析及干预建议[J]. 中国合理用药探索, 2023, 20(10): 89-95. ZHU Haibin, YU Jiazhu. Analysis on the use of Shugan Jieyu capsule in the outpatient clinic and emergency department of a hospital and intervention suggestions[J]. Chinese Journal of Rational Drug Use, 2023, 20(10): 89-95.
[46] Xu M, Li XM, Teng T, et al. Reconfiguration of structural and functional connectivity coupling in patient subgroups with adolescent depression[J]. JAMA Netw Open, 2024, 7(3): e241933. doi: 10.1001/jamanetworkopen.2024.1933
[47] Tozzi L, Zhang X, Pines A, et al. Personalized brain circuit scores identify clinically distinct biotypes in depression and anxiety[J]. Nat Med, 2024, 30(7): 2076-2087.
[1] XUE Ming, LIANG Jing, LING Bin. Research progress on characteristics and treatment of various endometriosis-associated pain [J]. Journal of Shandong University (Health Sciences), 2025, 63(10): 13-19.
[2] WANG Dan, YANG Xiaohua, ZHENG Yunshao, KAN Weijing, XUN Guanglei. Serum level of hs-CRP in patients with depression and its predictive role for the efficiency of antidepressants [J]. Journal of Shandong University (Health Sciences), 2018, 56(6): 51-57.
[3] CUI Yong, ZHANG Rongxiang, WANG Fuli, WANG Guoying, FENG Jianlin, ZHANG Haixia. Clinical efficacy of BSD2000 deep hyperthermia combined with chemotherapy of TP regimen for advanced ovarian cancer [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2015, 53(7): 53-57.
[4] WANG Hui. Clinical observation of triple therapy of moxifloxacin and esomeprazole magnesium for Helicobacter Pylori [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2014, 52(8): 52-56.
[5] WANG Jindong1,　JIAO Zhian2,　ZHAO Guoqing2,　LI Hui1. Curative effect of Zoloft for adjuvant treatment of teenagers′bronchial asthma accompanied by depression [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2010, 48(1): 109-112.
[6] . Antibiotics in reducing resistant mutants of Pseudomonas 
aeruginosa in vitro [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2009, 47(9): 25-27.
[7] HAN Chun-yan,SHENG Wei,HAN Jun-qing. Capecitabine combined with late course accelerated hyperfractionatedradiotherapy for esophageal cancer [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2008, 46(4): 427-429.
[8] FU Wei-jiang,YANG Qiu-an,HAN Wen-fei,FU Lei,GAO Shuang,PAN Zhen-hua,CHENG Xiao-guo. Clinical effect of concurrent chemoradiotherapy foradvanced esophageal cancer [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2008, 46(1): 84-87.
[9] HAO Jing,WANG Xiu-mei,YI Cui-hua,LI Li,WANG Xiu-wen,SUN Li-mei,YU Jin-ming. Health economical evaluation of four thirdgeneration chemotherapy regimens in advanced nonsmall lung cancer patients in China [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2007, 45(6): 616-620.
[10] WEI Hong,LI Jin-song,LIU Wen-jun. Expression and significance of c-kit in conventional osteosarcoma [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2007, 45(3): 243-245.
[11] BU Jie-qiong,YU Bao-fa. Slow intra-tumor release of drugs on B16 melonoma in mice [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2007, 45(10): 988-991.
[12] ZHANG Mei,ZHANG Yun,ZHAO Yu-xia,ZHANG Yuan-yuan,GAO Yue-hua,LI Xiu-chang. [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2006, 44(7): 662-665.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
Copyright 2018 © Editorial office of Journal of Shandong University (Health Sciences)
Supported by Beijing Magtech Co.Ltd